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Abstract 
Application of nanotechnology to medicine, usually termed as nanomedicine, has given a crucial 
impulse to the design of various drug-loaded nanocarriers driven by the idea to overcome the 
limits associated to the traditional delivery modalities, in particular in the field of cancer 
treatment. However, appropriate preclinical evaluation of the real therapeutic potential of 
nanomedicines suffers from the lack of relevant models, well representative of the human disease 
and good predictors of the therapeutic response in patients. In this context a great emphasis has 
been directed toward 3D tumor models aiming to surmount the insufficient predictive power of 
traditional 2D monolayer cultures of cancer cells. This review focuses on multicellular tumor 
spheroids (MCTS), which are so far the largest employed 3D tumor model in preclinical studies. 
After a brief discussion on spheroid construction strategies and analytical/imaging techniques 
employed in experimental settings, the application of 3D MCTS to the evaluation of 
nanomedicines displaying various physico-chemical properties is reviewed. Finally, relevant 
examples of scaffold and microfluidic systems in which MCTS have been included are 
described.  
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1. Introduction  
The efficacy of conventional therapies is often limited by a non-specific cell/tissue distribution 
of drugs, their rapid metabolization and/or excretion from the body. In this context, nanoscale 
systems for drug delivery (i.e., nanomedicines) have received in the last decades a tremendous 
attention because they hold the potential to overcome these limits, providing a solution to 
medical challenges that urgently require novel therapeutic strategies.1-3 Nanomedicines can 
indeed improve the therapeutic index of the transported drug by (i) offering protection from 
degradation, (ii) enabling controlled release and distribution and (iii) increasing bioavailability. 
In particular, being cancer one of the leading causes of death worldwide, much work has been 
done in this field with the aim to propose more efficient treatments. 
Accordingly, a plethora of well-engineered nanomedicines surface-modified with cell targeting 
ligands4 or endowed with stimuli-responsiveness5 has been designed. However, despite the 
encouraging results observed in preclinical experimental models as well as in clinical trials,6, 7 
the introduction of nanoscale drug delivery systems in the clinical practice is not 
straightforward,8, 9 and only a limited number of nanomedicine reached the market place. They 
include for instance lipid and natural protein-based nanomedicines such as the 
Doxorubicin(Doxo)-loaded liposomes (i.e., Doxil®, Myocet®) and paclitaxel albumin-bound 
nanoparticles (NPs) (i.e., Abraxane®). Noteworthy is that so far not any nanomedicine based on 
synthetic polymers has been introduced in the market in spite of the high versatility offered by 
the macromolecular synthesis and the possibility to opportunely tune the polymers properties 
(e.g., composition, structure, functionalization, degradability etc…).10-13 
It has to be noted that reaching the biological targets and ensuring sufficient drug delivery and 
accumulation is extremely challenging as consequence of the multiple biological barriers that 
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characterize tumors and their microenvironment, which are crossed by nanomedicines at low 
efficiency or not at all.14, 15 However, such biological transport barriers are generally not taken 
into account during in vitro preclinical evaluation of nanomedicines, the majority of which is still 
routinely carried out on two dimensional (2D) monocultures of isolated cancer cells. Despite 
their relative ease of handling, these cultures do not show any structural architecture and lack the 
complex physiology and the microenvironment of the real tumor tissues, which consist of 
different cell types (e.g., fibroblasts, macrophages, endothelial cells, immune cells) embedded in 
an extracellular matrix (ECM) mainly composed of fibrous proteins and proteoglicans.16-18 Cells 
cultured in 2D monolayers display altered gene expression and activation of signaling pathways 
compared to cells grown in the native tumor tissue.19 Moreover, growing in a single layer, they 
do not replicate neither (i) the cell-to-cell and cell-to-ECM interactions20-22 nor (ii) the oxygen, 
nutrients and pH gradients,23 which play a crucial role in tumor progression, chemoresistance 
and metastatic spread.24  
Accordingly, there is an urgent need for more relevant models capable to closely mimic the 
heterogeneity and the microenvironment of the in vivo condition thus allowing a more predictive 
in vitro evaluation of nanomedicines. In this context, three dimensional (3D) culture models such 
as multicellular spheroids (MCTS), polymer scaffolds and microfluidic systems have been 
proposed as an alternative approach to overcome the aforementioned limitations.25-32 
3D tumor models are indeed capable to recapitulate some key features of the real tumors thus 
representing a valuable tool for (i) a more accurate preclinical screening of nanomedicines and 
(ii) the identification of the candidates with the highest chances of success, which would be 
further evaluated in vivo. According to their predictive capacity, 3D models would enable to 
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limit the number of animals required in preclinical studies allowing to abide by the 3Rs 
guidelines.33, 34 
Although the application of 3D models for systematic assessment of therapeutic efficacy of 
nanomedicines is still at the beginning, their superiority compared to the 2D models is nowadays 
clearly acknowledged. This review will provide the reader with an overview of the application of 
multicellular tumor spheroids, the widest employed 3D tumor model so far, for evaluation of 
nanomedicines highlighting their usefulness as discriminating tool. In agreement with the scope 
of the journal, attention has been focused on drug delivery systems made of polymers or in 
which polymers have been used for surface modifications.  
 
2. 3D multicellular tumor spheroids  
Multicellular tumor spheroids are scaffold-free spherical self-assembled aggregates of cancer 
cells displaying an intermediate complexity between 2D in vitro cell cultures (i.e., cell 
monolayers) and in vivo solid tumors with which they share important similarities. Since their 
first introduction in the early 1970s by Sutherland and coworkers,35, 36 the application of 
multicellular tumor spheroids in drug discovery has grown exponentially, offering the possibility 
to screen a large variety of different molecules37-39 and they are currently considered a suitable 
3D model for drug evaluation in the oncology field.37, 40 
The physiological communication and the signaling established between cells growing in close 
contact make possible to reproduce in spheroids key aspects of the tumor and its 
microenvironment such as: (i) different cell proliferative rates, (ii) specific gene expression, (iii) 
deposition of ECM components, (iv) cell-to-cell and cell-to-microenvironment interactions and 
(v) drug resistance.40-42 Still, a limitation of MCTS relies on the fact that they mimic only the 
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avascular region of in vivo tumor tissues thus leaving out relevant aspects of real tumorigenesis 
such as the surrounding vasculature, the immune system components as well as the fluid 
dynamics.38, 41 
Large spheroids (~400-500 μm diameter) display an internal layered cell distribution analogous 
to that observed in solid tumors. This is the result of mass transport limitations, which interfere 
with the diffusion of oxygen, nutrients and metabolic wastes through the spheroid creating 
specific gradients.43, 44 Accordingly, thanks to the easier access to oxygen and nutrients, highly 
proliferating cells are located in the external layer of spheroids and correspond to tumor cells 
close to capillaries in vivo. Conversely, quiescent cells characterize the middle layer, because cell 
metabolism decreases progressively with the increasing distance from spheroid periphery. 
Finally, a critical situation characterizes the spheroid core in which the oxygen depletion (i.e., 
hypoxia), the nutrient shortage and the metabolic waste accumulation result in cell necrosis (Fig. 
1).40, 43-45 The organization in cell layers and the presence of diffusive gradients, acting as 
microenvironmental stresses, force the inner cells to a specific metabolic adaptation,43 
responsible of the observed impaired therapeutic efficacy of various anticancer drugs or drug-
loaded nanocarriers.40, 46 For instance, cells in the hypoxic region are resistant to drugs which 
promote cellular death through reactive oxygen species, while the existence of necrotic and 
quiescent cells reduces the therapeutic efficacy of drugs active against the proliferating ones.40 
Another important feature of MCTS is the presence of a network of structural (i.e., collagen and 
elastin) and adhesive (i.e., fibronectin and laminin) ECM proteins embedded in a gel of 
glycosaminoglycans and proteoglycans.40, 42 This microenvironment acts as a regulating factor 
influencing cell proliferation, differentiation and tumor growth.41, 43 In addition, it closely mimics 
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the physical barriers found in real solid tumors, which obstruct the free penetration of drugs 
thorough the whole mass.40  
Undoubtedly, the presence of this tumor microenvironment represents an advantage compared to 
the conventional monolayer cultures although it has to be noted that ECM components found in 
MCTS present a different cellular origin compared to those present in the in vivo tumor tissues. 
In the former, they are secreted by the same cancer cells forming the spheroids while in the latter 
by the tumor-associated fibroblasts (TAF).42 To face this issue, spheroids composed of cancer 
cells and components of the supportive stroma have been recently proposed.47, 48 These hetero-
type multicellular spheroids better reproduce the cellular heterogeneity of the tumor tissues and 
are expected to allow a more reliable evaluation of cancer cells-microenvironment interactions 
and their impact on the therapeutic outcomes.43, 47-49 
 
Fig. 1 Schematic representation of cell organization and gradients in tumor spheroids. Adapted 
with permission from ref. 44. Copyright 2008 Wiley-VCH. 
 
 
2.1. 3D MCTS culture methods 
Different techniques for spheroid construction are currently available and many of them have 
been optimized for large-scale production under highly reproducible conditions.40 Principally 
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they involve the use of cell attachment-resistant surfaces or physical forces to promote cell-to-
cell interactions and support the 3D spheroid formation (Fig. 2). These techniques will be briefly 
discussed in the following paragraphs while for a more detailed and extensive description the 
interested reader could refer to recently published reviews.38, 41, 45, 50, 51 
 
2.1.1. Liquid overlay methods 
This technique mainly relies on the use of non-adherent 96-well plates, in which a coating with 
poly-2-hydroxyethyl methacrylate (poly-HEMA)52-58 or agarose59-85 prevents cell attachment. 
This method allows to prepare both mono and hetero-type spheroids, whose size and morphology 
can be finely tuned by varying the number of cells seeded in each well.48, 50, 51, 86 The large 
number of produced spheroids and the ease of handling make this approach applicable to 
different kind of high-throughput investigations.51, 86 For instance, cells could be seeded using a 
bulk liquid dispenser or a liquid handling robot, which also offers the possibility of scaling-up 
the spheroid fabrication.37 Compared to the agitation-based approaches, the liquid overlay 
methods require lower volume of media, and testing materials (e.g., drugs).50, 87 However, a 
major drawback is the time-consuming plate-coating step. Although pre-coated low cell adhesion 
plates are commercially available (e.g., Ultra-low Attachment Surface from Corning®; 
PrimeSurface low adhesion culture plate from Sumitomo Bakelite Co.; Lipidure®-coated plates 
developed by NOF Corporation), their use increases the overall costs.38 
 
2.1.2. Hanging drop methods  
This technique exploits the surface tension to hang small cell suspension droplets (20-50 µL) on 
the underside of a tissue culture dish lid.44, 51 Then, gravity drives cells accumulation at the tip of 
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the drop (liquid-air interface) and induces their rapid aggregation into a single spheroid.44, 50 By 
changing the cell density, control of spheroid size has been achieved with a high reproducibility 
for numerous cell lines38 both in mono and co-cultures.47 However, the volume of the seeding 
suspension is generally limited and does not provide nutrients enough for a long term culture.44, 
50 Therefore, once formed, spheroids need to be transferred on 96-well plates or embedded in 
polymer matrices for further studies.88-95 Not only such transfer can affect the integrity of 
spheroids but clearly makes this technique extremely labor intensive and time-consuming thus 
preventing large scale application.44, 50, 51 Commercially available platforms (InSphero 
GravityPlus™ technology and PERFECTA3D™ hanging drop plates of 3D Biomatrix) can 
reduce the workload and enable to carry out experiments in a high-throughput manner, although 
with a significant increase of the expenses. 
 
2.1.3. Agitation-based approaches 
Spinner flasks and rotational culture systems (i.e., NASA Rotary Cell Culture System) are 
bioreactors in which cell aggregation and spheroid formation are mediated by a continuous 
spinning that keeps in motion a cell suspension supporting cell-to-cell interactions and avoiding 
their attachment to the container wall.38 The movement of the medium provides a controlled 
environment and maintains the transport of nutrients and waste allowing (i) long-term culture 
and (ii) large-scale production. However, although by tuning cell-seeding density, spinning rate 
and culture time it is possibly to influence the average spheroid diameter,44 the overall control on 
the number of cells per spheroid and their size is extremely poor.38, 50 Therefore, manual 
selection of similarly sized spheroids and their transfer in different supports are mandatory 
before any further assay (e.g., cytotoxicity, penetration, etc…).96-98 
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To be noted that only cell lines that can withstand to high shear stress can be cultured in spinner 
flasks.38, 50 For less resistant cells types, the NASA Rotary Cell Culture System characterized by 
lower shear forces, thanks to simultaneous rotation of the culture chamber together with its 
content, should be instead preferred.38, 44 However, both approaches require specialized 
equipment and large amount of culture media, which therefore limit their large application.38 
 
2.1.4. Patterned surfaces and microfluidic devices 
Patterned surfaces in combination or not with microfluidics devices have been recently 
developed and offer a new range of advanced strategies for spheroid construction.37, 38, 99-102 For 
instance, spheroids with defined size and composition have been generated using arrays of 
microwells fabricated with the micromolding or the photolithography technique.37, 44, 45, 103, 104 
Low attachment surfaces have been obtained using non-adherent materials such as the 
poly(dimethylsiloxane) (PDMS) 46, 105, 106 or applying a coating of agarose 107-110 or Pluronic® F-
127.48 Compatible with traditional well plate formats and microscopes, such microwell plates are 
suitable for high-throughput screening.111  
Similarly, formation of cellular aggregates in a controlled environment and with high 
simplification of the liquid handling procedures has been obtained with microfluidic systems 
containing various micro-sized chambers and channels.45, 50, 102 Requiring only limited amounts 
of cells, media and reagents they are extremely attractive and convenient for drug screening 
applications, however the impossibility to retrieve and extensively characterize the formed 
spheroids is a general drawback of these approaches.38, 111 Further level of complexity is 
achieved with microfluidic devices displaying (i) distinct compartments loaded with different 
cell types (e.g., epithelial cells, endothelial cells and fibroblast), (ii) collagen gel inserts and (iii) 
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variously shaped channels, which ensure the cell-to-cell chemical communication thus 
mimicking the complex in vivo-like organizations.111-113 Nevertheless up to now the complexity 
and the costs of the equipment required for their use have hindered their wide application in 
preclinical investigation of nanomedicines. 
 
 
Fig. 2 Schematic representation of the main techniques used for spheroid construction: (a) liquid 
overlay; (b) hanging drop method; (c) spinner flask; (d) NASA bioreactor; (e) micromolding 
microwells. Adapted with permission from ref. 50. Copyright 2013 American Chemical Society. 
 
 
2.2. End-points assessment in 3D MCTS  
Thanks to the capacity to recreate key features of the real tumors, 3D MCTS have been largely 
used for the assessment of the efficacy of various therapeutic strategies. In this context, assays 
and detection methods specific for the 3D cultures are highly required to carry out an accurate 
and predictive evaluation. Being their detailed description out of the scope of this review, the 
most common techniques are only summarized in the next paragraphs, while a comprehensive 
presentation can be found in recently published articles.37, 39-41, 45 
Optical microscopy is the simplest and most widely used technique for the visual assessment of 
morphological changes in spheroids.52, 55-58, 60-65, 70, 73, 74, 77, 84, 89-93, 95, 107, 110, 114-126 Following 
exposure to various treatments, the measure of the variation of morphometric parameters (e.g., 
mean diameter, minimum diameter, maximum diameter, volume, area and circularity) of 
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spheroids from bright field images is used for a quantitative analysis of the extent of growth 
inhibition.37, 87 After interruption of the treatment, the spheroid growth delay might be calculated 
in comparison to untreated samples as the time lag required to reach the quintuple spheroid 
volume of day 4 (5 × Vd4; assuming Vd4 as the starting spheroid volume at the onset of 
treatment).87 
The assays currently used in 2D monolayer cultures as extensively validated methods to assess 
the drug cytotoxicity mainly rely on the measurement of (i) cell membrane integrity (i.e., LDH 
assay)127 or (ii) intracellular metabolic activity (e.g., MTT, WTS-1, AlamarBlue® assays).128 
Some of them have been adapted to spheroids and are currently commercially available. Among 
them, the quantification of the Acid Phosphatase (APH) activity and the intracellular adenosine 
triphosphate (ATP) level are well-suited assays that do not require preliminary dissociation of 
spheroids into single-cell suspensions.37, 45 The APH assay is a simple and inexpensive technique 
based on the quantification of cytosolic acid phosphatase activity in viable cells through the 
measurement of the absorption of the p-nitrophenol, obtained by APH hydrolyzation of p-
nitrophenyl phosphate, at 405 nm using any standard plate detection reader.37, 129 The APH assay 
has been validated to measure spheroid viability and cytotoxic effects of both free drugs 87, 129 
and drug-loaded nanocarriers.82, 95, 115, 124 
The ATP assay exploits the oxidation of the luciferin, the substrate of the firefly luciferase 
enzymes, in presence of O2, Mg
2+ and ATP. This reaction brings the luciferin to an electronically 
excited state, which then decays with the emission of a photon of light (i.e., bioluminescence). 
Thus, when substrate and enzyme are added to cell cultures the light output, which is directly 
proportional to the intracellular ATP content (marker of metabolically active cells), allows to 
quantify the number of viable cells. Ready-to-use assay kits, which exploit the high sensitivity 
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and the low background of the bioluminescence signal45 (e.g., CellTiter-Glo® 3D Cell Viability 
Assay (Promega); Molecular Probes® ATP Determination Kit (Invitrogen,)) are currently 
available. The CellTiter-Glo® 3D Cell Viability Assay represents a time-effective and well 
standardized assay since the addition of a single reagent directly to the 3D cell culture results 
into cell lysis and simultaneous generation of the bioluminescence.130 This assay is especially 
formulated with robust lytic capacity to overcome 3D MCTS obstacles such as tight cell-cell 
junctions and the presence of the extracellular matrix.130 The relatively simple workflow and data 
analysis make this ATP assay scalable to high-throughput screenings of drug-loaded nanocarrier 
efficacy.125  
Qualitative assessment of proliferating or dead/necrotic cells can be performed by Confocal 
Laser Scanning Microscopy (CLSM) imaging following spheroid incubation with various 
live/dead reagents.46, 118, 131 Preliminary spheroid dissociation into single cells is instead required 
for a quantitative measurement by Fluorescence-Activated Cell Sorting (FACS).70 Staining cell 
dispersions of dissociated spheroids with fluorescently labeled Annexin V (AnnexinV-FITC) and 
propidium iodide (PI) has also been largely used to detect early apoptotic and dead/necrotic cells, 
respectively.96, 132-134 Apoptosis can be detected also on spheroid cross-sections by using the 
Terminal deoxynucleotidyl Transferase (TdT) dUTP Nick-End Labeling (TUNEL) method. The 
TdT recognition of the blunt ends of double stranded DNA breaks, which characterizes the late 
stages of apoptosis,135 catalyzes the addition of biotinylated dUTPs that are then visualized using 
streptavidin-conjugated detection agents (i.e., peroxidase or fluorescent markers).56, 136 
Monitoring of fluorescent drugs and dye-labeled nanocarriers by CLSM has been largely applied 
for evaluating their uptake and penetration in individual spheroids.63, 66, 69, 76, 95, 105, 133 
Unfortunately, compared to conventional 2D cultures, the 3D structure represents a technical 
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challenge for conventional instrumentation. Indeed, the increase of spheroid size and thickness 
result in loss of image quality due to scattering, reflection and absorbance of light.37, 41 The 
layered structure of spheroids limits the inner scanning depth and, as consequence, the 
penetration ability of different systems can be compared only on a portion of the spheroid 
generally corresponding to a depth of 80-100 µm from the spheroid surface.63, 76, 95, 131, 137 
Although more time consuming, a better information on the real depth of penetration can be 
provided by acquisition of fluorescent images from serial sections obtained from fixed 
spheroids.46, 71, 88, 96-98, 138, 139 
Compared to traditional CLSM, significant improvements in the evaluation of the penetration in 
living tumor spheroids can be obtained with Two-Photon (TPM) or Multi-Photon microscopy 
(MPM) in which the energies of two (or more) photons are combined to promote the transition of 
a fluorescent marker to an excited state.140 The use of excitation wavelength in the NIR region 
(700-1000 nm) offers the possibility to increase the laser penetration into 3D MCTS (up to 500-
800 μm according to the instrumentation) with low phototoxic effects.50, 140 These techniques 
have been already applied to visualize with high resolution the diffusion through spheroids of 
various polymer-based nanocarriers.70, 81, 85, 120, 137, 141 Imaging cellular processes and drug 
delivery in spheroids with an even superior 3D isotropic resolution and limited photodamage are 
the promises of Light-Sheet Fluorescent Microscopy (LSFM) methods such as the Selective 
Plane Illumination Microscopy (SPIM)47, 142, 143 already applied to the imaging of large 
biological samples.144, 145 However so far they have not found application yet in the preclinical 
investigation of polymer nanomedicines. 
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Table 1. Methods used for the evaluation of polymer-based anticancer nanomedicines on 3D MCTS 
Analyzed 
Parameter  
Assay/Detection 
methods 
Description/Principle Reference 
Cell viability/ 
Cytotoxicity 
3-(4,5-dimethyl-2-
thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide 
(MTT) a,b 
Evaluation of intracellular metabolic activity. 
Reduction of the MTT tetrazolium salt into an insoluble formazan product 
by the mitochondrial NADPH dehydrogenases. 
Absorbance measurement at 570 nm. 
 
71  
2-(2-methoxy-4-
nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-
disulfophenyl)-2-
tetrazolium (WST-1) a,b 
Evaluation of intracellular metabolic activity. 
Reduction of the WST-1 into a water soluble formazan by the NADH 
dehydrogenase and plasma membrane electron transport. 
Absorbance measurement at 450 nm.  
 
122, 123 
3-(4,5-dimethylthiazol-2-
yl)-5-(3-
carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-
tetrazolium (MTS) a,b 
Evaluation of intracellular metabolic activity. 
Reduction of the MTS tetrazolium salt into an water soluble formazan 
product by the mitochondrial NADPH dehydrogenases.  
Absorbance measurement at 490 nm. 
 
65, 88 
AlamarBlue® a,b Evaluation of cellular reducing ability. 
Reduction of resazurin to resorufin. 
Fluorescence measurement. Ex 540–570 nm/Em 580–610 nm. 
110, 146 
Acid phosphatase 
(APH)b 
Quantification of APH activity. 
Hydrolysis of p-nitrophenyl phosphate in p-nitrophenol by the APH 
enzyme.  
Absorbance measurement at 405 nm.  
 
82, 95, 115, 124 
Adenosine triphosphate 
(ATP) b 
Measurement of the intracellular ATP content. 
Oxidation of luciferin by the luciferase enzymes in presence of 
intracellular ATP and emission of bioluminescence. 
66, 67, 120, 125 
Lactate dehydrogenase 
(LDH) a, 
Evaluation of membrane integrity. 
Measurement of conversion of lactate into pyruvate via NAD+ reduction 
by the LDH. The resulting NADH catalyzed the reduction of a 
53, 136 
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tetrazolium salt to a formazan product.  
Absorbance measurement at 450 nm.  
 
DNA quantification a Quantification of total cell number.  
Hoechst 33258 staining.  
Fluorescence measurement following lyophilization and lysis of 
spheroids. 
 
90, 91 
Growth 
inhibition 
Optical microscopy c Measurement of morphometric parameters (e.g., mean diameter, 
minimum diameter, maximum diameter, volume, area and circularity).  
52, 55-58, 60-
65, 70, 73, 74, 
77, 84, 89-93, 
95, 107, 110, 
114-126 
Morphological 
effects  
Scanning electron 
microscopy (SEM) c 
Assessment of spheroid integrity.  
 
46, 55, 57, 63, 
64, 70, 73 
Cell death/ 
Apoptosis/ 
 
Trypan Blue exclusion a  Quantification of living cells.  
Trypan blue staining of dead cells.  
46, 70, 118, 
126, 131 
Live/Dead staining Distinction and quantification of living and dead cells. 
Staining with calcein-acetoxymethyl (calcein-AM) and intercalating 
agents (e.g., propidium iodide (PI) or ethidium homodimer (EthD-1)). 
Live cells are stained in green following intracellular cleavage of the 
acetomethoxy group of calcein-AM. Dead cells are stained in red 
following penetration of the intercalating agents through their permeable 
membrane. 
 
46, 70, 118, 133 
AnnexinV-FITC staining Detection of the apoptosis marker phosphatidyl serine on the cell 
membrane surface with Annexin V-FITC. Used in combination with PI 
staining to distinguish apoptotic and necrotic cells.  
 
96, 133, 134 
Caspase-3 activation  Quantification of caspase-3 activity via measurement of fluorescent 
emission of activate-caspase-3 substrates. 
 
 
54, 118 
17 
 
Terminal 
deoxynucleotidyl 
transferase (TdT) d UTP 
Nick- End Labeling 
(TUNEL) 
Quantification of DNA fragmentation as marker of late apoptosis. 
Detection of double stranded DNA breaks via TdT-mediated 
incorporation of labeled dUTP to their blunt ends. 
 
56, 136 
 
Penetration/ 
Uptake of 
fluorescently 
labeled 
nanocarriers 
and dyes 
Confocal Laser Scanning 
Microscopy (CLSM)c 
Visual evaluation of nanocarrier diffusion ability. 
Pinhole-equipped microscope to remove out-of-focus light and increase 
optical resolution.  
Light penetration depth limited to 100-150 µm from spheroid surface. 
 
48, 53-60, 62-
64, 66-69, 72, 
74-76, 78-80, 
83, 84, 89-91, 
94, 95, 105-109, 
115, 117-119, 
122-126, 131, 
133, 134, 136, 
137, 146-157 
Two-photon microscopy 
(TPM) and multi-photon 
microscopy (MPM)c 
Visual evaluation of nanocarrier diffusion ability. 
Sample excitation with pulsed long-wavelength photons. 
Increase of image resolution and depth of penetration (up to 500-800 µm). 
 
70, 81, 85, 120, 
137, 141 
Fluorescence-Activated 
Cell Sorting (FACS)a 
Quantification of cell internalized fluorescence. 71, 78, 85, 122, 
134, 136 
Fluorescence microscopy Visual evaluation of nanocarrier diffusion ability. 
Imaging of fixed, optimal cutting temperature (O.C.T.) embedded 
spheroids cross-sections. 
 
46, 71, 88, 96-
98, 138, 139 
 
 
a Preliminary cell dissociation required. 
b Quantification of metabolically active cells. 
c Imaging of intact spheroids. 
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2.3. Use of 3D MCTS to screen polymer nanocarriers with different physico-chemical 
properties 
Distinguishing characteristics of polymer nanocarriers, such as chemical composition, size, 
shape and surface properties might strongly affect their capacity to diffuse into tumors and 
therefore have a profound impact on their anticancer efficacy.158 Accordingly, these parameters 
must be taken into account during the design and evaluation of any novel nanomedicine. In this 
context the 3D MCTS models, thanks to their similarity in morphology and biological 
microenvironment to solid tumors, have already been used as robust tool for easy polymer 
nanoparticle screening,70, 97 and to accurately predict the in vivo behavior of the nanocarriers as 
function of their specific physico-chemical properties.139 The most relevant results will be 
discussed in the following sessions.  
 
2.3.1. The size effect 
The influence of size on the penetration profile of nanoscale systems has been clearly highlighted 
and, according to the general trend observed in vitro with 3D MCTS and further confirmed in 
vivo, it is evident that the diffusion capacity is inversely correlated to the particle size.56, 72, 97, 98, 
139, 148 For instance, nanogels obtained by chelating ligands-modified hyaluronic acid were able 
of deeper penetration into MKN74 gastric cancer spheroids compared to the polymer in the 
linear form and their small size (21 nm) ensured a uniform distribution over the entire 3D 
mass.106 Similarly, following release from poly(ethylene glycol) (PEG)-poly(d,l-lactide) (PLA) 
nanoparticles, in which they have been loaded, small polyamidoamine (PAMAM) dendrimers 
(G2, 2 nm) penetrated efficiently into the core of KB papilloma cells spheroids (diameter ~ 50 
µm) compared to their larger counterparts (G4 (5 nm) and G7 (7 nm)) whose florescent signal 
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was detected only in the peripheral rim.72 Noteworthy is that the size plays a major role in the 
capacity of tumor penetration even in case of surface functionalization with specific ligands. By 
using a murine breast cancer MCTS model (4T1 cells) it was observed that RGD 
functionalization endowed Pluronic F127-coated paclitaxel (Ptx) nanocrystals with better 
penetration ability compared to the free drug (Taxol) and to the non-functionalized carriers. 
However, for nanocrystals displaying similar functionalization, a smaller size (10 nm vs 70 nm) 
conferred a greater advantage in terms of depth of penetration (Fig. 3a).56 It has to be noted that 
not any difference was observed when the particles were evaluated on a 2D culture model, thus 
highlighting the usefulness of the 3D MCTS to discern the crucial role of the size. TUNEL 
staining of spheroid’s cross-sections revealed that the deeper penetration was associated to a 
more extensive cell apoptosis, which caused spheroid growth inhibition and their further collapse 
following prolonged drug exposure (Fig. 3b, c).56 
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Fig. 3 Tissue penetration and antitumor efficacy on 4T1 MCTS of Taxol, ∼70 nm Ptx 
nanocrystals (NPs), RGD-grafted ∼70 nm Ptx nanocrystals (iNPs), ∼10nm Ptx nanocrystals 
(NDs) and RGD-grafted ∼10nm Ptx nanocrystals (iNDs). (a) CLSM images after 24 h 
incubation with Cy5-labeled Taxol/NDs/NPs/iNDs/iNPs, (b) CLSM images of TUNEL analysis 
after 24 h treatment with the different Ptx formulations; dead cells are red and live cells appear in 
green. (c) Growth inhibitory effect of the different formulations. Reproduced with permission 
from ref. 56. Copyright 2015 WILEY-VCH. 
 
 
In spite of these results, the identification in vitro of the optimal size of a nanocarrier to achieve 
the highest drug delivery in vivo is extremely complex because although MCTS closely mimic 
the tumor tissues they lack of predictive value in terms of pharmacokinetics and biodistribution. 
Accordingly, evaluation of nanomedicines in animal tumor models still remains a mandatory 
step to assess these parameters. It has been indeed shown that the requirements for tumor 
penetration and tumor retention are often in contradiction to each other. Thus, despite 
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unfavorable for penetration in the tumor mass, due to their considerable diffusional hindrance,159 
nanocarriers with a size of around 100 nm, are the most advantageous in improving 
pharmacokinetics and extravasation.160 On the other hand, smaller nanocarriers show much 
better penetration in the tumor interstitial space.139, 148 However, for extremely small particles ( ≤ 
5.5 nm), rapid clearance from tumors and short half-life have been observed.161 To face this 
issue, the ideal drug delivery system should be able to shrink and adapt its size in response to the 
encountered microenvironment. Interestingly, size-switchable stimuli-responsive nanoparticles 
able to overcome multiple tumor barriers have been developed by various groups.58, 76, 119, 133, 134, 
138, 141 For instance, pH sensitive nanoparticles were formulated by the molecular assembly of 
platinum (PtIV)-prodrug conjugated polyamidoamine (PAMAM) dendrimers with two 
amphiphilic polymers contain either ionizable pH-responsive amide bonds (i.e., 
polycaprolactone-2-propionic-3-methylmaleic anhydride (PCL-CDM), PCL-CDM-PAMAM/Pt 
nanoparticles)134 or tertiary amine groups (i.e., poly(ethylene glycol)-b-poly(2-azepane ethyl 
methacrylate) (PEG-b-PAEMA) PEG-b-PAEMA-PAMAM/Pt) (Fig. 4a).133 Size variation as 
function of pH has been evaluated on pancreatic cancer multicellular spheroids (BxPC3 cells). At 
physiological pH the clustered nanoparticles (i.e., pH-sensitive cluster nanobombs (SCNs/Pt)) 
displayed a size of around 100 nm, while the pH drop (from 7.4 to 6.5-7) in the tumor 
extracellular space triggered an instantaneous disassembly of these pH sensitive nanoparticles in 
small Pt-PAMAM prodrugs (≈5 nm) able to penetrate deeply and uniformly into the spheroid 
mass (Fig. 4b). Then, once internalized, the intracellular redox environment led to the release of 
the active molecule (i.e., Pt(II) species) resulting in significant cell apoptosis. As expected a 
higher cell viability was observed when spheroids were incubated with pH-insensitive 
nanoparticles (i.e., ICNs), which demonstrated limited capacity of penetration and drug delivery 
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as a consequence of their stable size (Fig. 4b). Whether such advantage was maintained in vivo 
was then assessed after intravenous injection of both nanoparticles in an experimental model of 
pancreatic cancer (BxPC3 cancer cells) characterized by an important desmoplastic reaction and 
limited permeability.162 Tumor accumulation studies confirmed a higher capacity of penetration 
of pH-sensitive nanoparticles, which diffused in the tumor interstitium, after vessel 
extravasation, for several hundreds of nanometers. On the contrary, the pH-insensitive NPs 
accumulated in the tumor vessels with little penetration in the tumor mass (Fig. 4c) leading to an 
inefficient drug delivery. In agreement with the in vitro results, an extensive apoptosis was 
detected in tumor sections of mice treated with the pH-sensitive nanoparticles, thus confirming 
the predictive potential of the 3D multicellular spheroids.  
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Fig. 4 (a) Structure of PEG-b-PAEMA-PAMAM/Pt and schematic illustration showing the self-
assembly into the pH-sensitive cluster nanobombs (SCNs/Pt) at neutral pH and the disintegration 
of into small particles at tumor acidic pH. (b) CLSM images showing in vitro penetration of 
fluorescently-labeled SCNs/Cy5 and ICNs/Cy5 in BxPC-3 multicellular spheroids. Scale bar: 
100 μm. (c) In vivo real-time microdistribution of SCNs/Cy5 and ICNs/Cy5 in BxPC-3 
xenografts after intravenous administration. Scale bar: 100 μm. Reproduced with permission 
from ref. 133. Copyright 2016 American Chemical Society. 
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2.3.2. The shape effect 
 
3D tumor spheroids have found application also for the early screening of nanocarriers with 
different shape (i.e., spherical vs elongated such as filaments, rod-like or worm-like vectors). 
However, whether this parameter may positively or negatively affect the nanocarriers 
penetration, the cellular uptake and the therapeutic efficacy still remains matter of debate.85, 120, 
147 For instance, when worm-like poly(ethylene oxide-b-ε-caprolactone) (PEO-PCL) 
photosensitizer-loaded micelles were compared to spherical ones on 3D models of colon (HCT-
116 cells) and head and neck cancer (FaDu cells), surprisingly not any advantage in terms of 
photodynamic therapy efficiency was observed in contradiction with the previously reported 
superior uptake of so-called "filomicelles".163 Nevertheless, the different size of the studied 
systems as well as other parameters such as the nanocarrier length, rigidity and surface properties 
might explain such differences and would need to be further explored.120 
The influence of length was studied by Stenzel and coworkers, which investigated rod-shaped 
poly(1-O-methacryloyl-β-D-fructopyranose)-b-poly-(methyl methacrylate) (poly(1-O-MAFru)-
b-PMMA)-based micelles, clearly showing that, among the various fructose-coated rod-like 
micelles, the shortest ones displayed the highest capacity of penetration in a 3D MCTS of breast 
cancer cells (MCF-7).147 Similarly, in order to better highlight the role of these parameters, 
poly(ethylene glycol) diacrylate (PEGDA)-based anionic nanohydrogels were synthetized by Jet 
and Flash Imprint Lithography in form of disk-shaped nanocylinders and cuboidal nanorods of 
two different sizes (low and high aspect ratio; aspect ratio (H/D) = height/diameter).85 The 
resulting nanohydrogels displayed negative charge of ~ -55 mV, which should limit the 
interactions with cell membranes and serum proteins and promote their penetration into HEK293 
spheroids (human embryonic kidney cells). Fluorescent intensity analysis of Two-Photon 
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microscopy images revealed a two folds higher accumulation near the spheroid outer half of the 
disk-shaped nanocylinders with the lowest aspect ratio (H/D ~ 0.3, 325 nm diameter and 100 nm 
height) (Fig. 5f) compared to both nanocylinders with higher aspect ratio (H/D ~0.45) (Fig. 5e) 
and nanorods (Fig. 5g,h). Such preferential penetration might be attributed to their larger surface 
contact area, which promoted the interaction with the cells and the diffusion (either passive or 
active) across the 3D tumor mass.  
 
Fig. 5 Uptake and penetration of shape specific particles in spheroid. Scanning Electron 
Microscope (SEM) images of (a) 220 nm × 100 nm disks (H/D ~0.45), (b) 325 nm × 100 nm 
disks (H/D ~0.3), (c) 400 nm × 100 nm × 100 nm rods and (d) 800 nm × 100 nm × 100 nm rods. 
(e-h) Two-Photon pictures of spheroids incubated with the disks or rods in the correspondent 
upper panel. (i) Normalized radial intensity distribution as a function of distance from the center 
of the spheroid. Reproduced with permission from ref. 85. Copyright 2015 Wiley-VCH. 
 
 
2.3.3. The charge effect  
 
As observed for shape and size, also the surface charge of the nanocarriers might also affect 
tissue penetration and efficient drug delivery.72, 82, 164, 165 For instance, the penetrating capacities 
of PAMAM dendrimers were discriminated according to their size (see 2.3.1.), but also a charge 
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effect was clearly observed showing that only the amino-modified (positively-charged) ones 
were capable of significant accumulation in the outer layers of breast cancer (MCF7 cells) tumor 
spheroids while negatively and neutral ones were completely excluded (Fig. 6a).72 Noteworthy is 
that small G2-NH2 dendrimers penetrated deeper than the larger G7-NH2 ones (214 ± 36 μm vs 
81 ± 8.31 μm), but surface accumulation was directly proportional to the dendrimer generation 
(G7 > G2) and therefore to the surface charge density (i.e., number of NH2 groups) (Fig. 6b). 
This behavior was correlated to the different strength of dendrimers-cells interaction: while it 
was negligible for the G2 dendrimers leading to low accumulation and fast penetration by 
paracellular diffusion, the firmer interaction of G7 ones led to a strong uptake, which however 
translated to a low diffusion via a transcellular mechanism.  
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Fig. 6 (a) Accumulation and permeation behaviors of G2, G4, and G7 PAMAM dendrimers in 
MCF-7 MCTS as function of the surface charge. (b) Tumor penetration of amine-terminated G2, 
G4, and G7 PAMAM dendrimers. Reproduced with permission from ref. 72. Copyright 2016 
American Chemical Society. 
 
The key role of a positive surface charge in the accumulation into multicellular spheroids has 
been observed also by comparing gold nanorods (AuNRs) (55 nm length x 14 nm diameter) 
coated either with (i) cetyltrimethylammonium bromide (CTAB) and 
poly(diallyldimethylammonium chloride) (PDDAC), or (ii) polystyrene sulfonate (PSS) 
displaying a surface charge of +40-50 mV or -25 mV, respectively.82 When incubated with 
MCF-7 breast cancer MCTS, the coating with a cationic polymer ensured the highest gold 
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accumulation, which was expected to induce strong photothermal cytotoxicity after NIR 
irradiation as it was observed in 2D monolayer cultures. However, despite their tendency to be 
largely retained, irradiation of these positively charged AuNRs led to a 40% lower hyperthermia 
efficacy compared to the negatively charged PSS-coated AuNRs. Such unexpected behavior was 
related to the different penetration capacity of the different AuNRs. Indeed, cationic polymer-
coated AuNRs highly accumulated in the spheroids but only in the outer region and simple 
surface adsorption was also observed. Moreover the interaction with negatively-charged serum 
proteins led to an increase of their size preventing diffusion. On the contrary, the negative charge 
of PSS-coated AuNRs allowed a more homogeneous distribution in the spheroid core, which 
resulted in higher viability loss and destruction of the inner compact spheroid structure.  
 
2.3.4. The role of the chemical composition  
3D multicellular spheroids have been used to discern whether the chemical composition of the 
polymer building blocks could affect the drug delivery efficacy of the resulting nanoparticles.60, 
91, 96, 152, 153, 155 Thus, curcumin-loaded biodegradable and non-biodegradable nanoparticles 
prepared by self-assembly of bovine serum albumin (BSA) conjugated with poly-(ε-
caprolactone) (PCL) or poly(methyl methacrylate) (PMMA) were investigated on LNCaP 
prostate cancer MCTS in comparison to conventional 2D cultures.91 The latter did not reveal 
appreciable differences between the two types of nanoparticles, which were both rapidly taken 
up by cells and induced similar cytotoxicity. On the contrary, the MTCS allowed to detect the 
faster and deeper accumulation of BSA-PMMA NPs, which occurred via a rapid sequence of 
endo and exocytosis events. However, such high penetration rate hindered a sufficient 
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intracellular drug release thus leading to a lower cytotoxicity compared to the BSA-PCL NP, 
whose biodegradability ensured, on the contrary, high intracellular drug concentrations (Fig. 7a).  
Non-biodegradable BSA-PMMA NPs induced a growth inhibition comparable to the 
biodegradable NPs, only when tested at 5 times higher drug concentration (Fig. 7b).  
 
 
 
 
Fig. 7 (a) Absorbance values (mean ± standard error) corresponding to the DNA content in 
LNCaP spheroids treated with curcumin-loaded nanoparticles for 7 days. (Curcumin 
concentration: 30 µM). ***p < 0.001. ****, p < 0.0001. (b) LNCaP spheroids treated with free 
curcumin and curcumin-loaded nanoparticles for 7 days. (Curcumin concentration: 150 µM). 
Scale bars: 200 μm. Reproduced with permission from ref. 91. Copyright 2016 Royal Society of 
Chemistry. 
 
 
Other examples of anticancer drug-loaded biodegradable nanocarriers evaluated on 3D spheroids 
included milk protein nanoparticles153 and micelles composed of either (i) pseudo block 
copolymers formed by the assembly of β-cyclodextrin terminated multi armed poly(N-
vinylpyrrolidone) (PVP) and adamantane functionalized polycaprolactone (PCL)155 or (ii) poly 
(ethylene oxide)-poly [(R)-3-hydroxybutyrate]-poly (ethylene oxide) triblock copolymers.96 The 
capacity of penetration of these nanosystems in 3D models was consistent with further in vivo 
experiments thus supporting the predictive capacity of the tumor spheroids.96, 153, 155  
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2.3.5. The role of the crosslinking 
The capacity of amphiphilic block copolymers to self-assemble in water as micelles has been 
largely applied for efficient drug delivery.90, 120, 124, 166, 167 Micelles display a typical core-shell 
structure and a variety of crosslinking strategies has been proposed to reach a higher stability. 
For instance the irreversible crosslinking of poly(ethylene glycol methyl ether acrylate)-b-
poly(carboxyethyl acrylate) (POEGMEA-b-PCEA) micelles with 1,8-diaminooctane90, 124 
protected against disassembly leading to better cellular uptake when compared to uncrosslinked 
counterparts. However, such crosslink induced a reduction of the drug release, leading to 
micelles with lower cytotoxicity compared to the free drugs when evaluated on 2D monolayer 
cell cultures of human prostate carcinoma (LNCaP cells).124 Analogous results have been 
obtained when glycol dimethacrylate (EGDMA) crosslinked poly(ethyleneoxide-b-3-
caprolactone) (PEO-PCL) have been investigated on HCT-116 (human colorectal carcinoma) 
and FaDu cells (human squamous cell carcinoma).120 On the contrary, the aforementioned 
micelles were characterized by superior antitumor activities than the free drug in different MCTS 
made with HCT-116, FaDu or LNCaP cells,120, 124 clearly demonstrating the limited predictive 
potential of 2D cultures in the assessment of the real value of nanocarriers as drug delivery 
systems. 
Whether the crosslink could affect the mechanism and depth of penetration as well as the 
cytotoxicity of drug-loaded micelles has been recently investigated by the group of Stenzel using 
pancreatic (AsPc-1 cells) multicellular tumor spheroids.90 Hence, 1,8-diaminooctane-crosslinked 
poly(N-(2-hydroxypropyl) methacrylamide-co-methacrylicacid)-block-poly(methyl 
methacrylate) (P(HPMAco-MAA)-b-PMMA) micelles (CKM) were compared to their 
uncrosslinked version (UCM) (Fig. 8a). Results revealed that CKM were capable of moving 
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through the cell layers via a transcellular process and delivered higher doxorubicin amounts to 
the spheroid core which resulted in greater cytotoxicity compared to the UCM (Fig. 8b,c,d). The 
latter quickly disassembled after penetration into the cells of the outer layers, releasing the 
loaded drug and causing cell death. As a result, no further micelle transcytosis could occur. The 
lower efficacy of the free drug (evaluated in terms of DNA content and inhibition of spheroid 
growth) correlated with its limited diffusion.90  
Nevertheless, the crosslinking is not always the best strategy to improve drug cytotoxicity. Thus, 
the evaluation of the effect of the reversible disulfide core-crosslinker cystamine in micelles 
formed by poly(ethyleneglycol methyl ether acrylate)-b-poly(carboxyethyl acrylate) 
(POEGMEA-b-PCEA) block copolymer,95 led to results in clear contrast to those previously 
published by the same group of Stenzel.90, 124 Indeed, the micelles with the highest level of 
crosslinking were capable of the deepest penetration in LNCaP prostate multicellular tumor 
spheroids, but displayed the lowest cytotoxicity. This behavior could be explained by a too 
compact structure that hindered intracellular reductive agents (e.g., glutathione) to diffuse in the 
core of the micelles thus slowing down cross-linked micelles disassembly and release of the 
loaded drug.95 Compared to the 2D monolayer cultures, the 3D spheroid model would provide a 
reliable correlation between micelles penetration and cytotoxicity, thus allowing figuring out the 
real contribution of the crosslinking in terms of drug delivery efficiency.  
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Fig. 8 (a) Schematic representation of the synthesis of block copolymer and formation of UCM 
and CKM. (b) Schematic hypothesis of penetration differences for Doxo-loaded CKM and UCM. 
(c) Doxo delivery into pancreatic MCTS by CKM and UCM revealed by CLSM. (d) Inhibition 
of the pancreatic MCTS growth by Doxo-loaded micelles. Microphotographs of pancreatic 
spheroids before and after treatment with Doxo-loaded micelles, free drug (Doxo-h) or untreated 
(Cont). Reproduced with permission from ref. 90. Copyright 2015 Royal Society of Chemistry. 
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2.3.6. The role of targeting ligands 
Functionalization of polymer nanocarrier surface with various ligands has been largely exploited 
as strategy for selective cell targeting.4 As discussed in the following sections, MCTS are 
currently widely used in order to assess the effectiveness of such modifications and evaluate the 
tumoral behavior of targeted nanoparticles. 
 
2.3.6.1. Transferrin-targeted nanocarriers 
Overexpression of transferrin receptor (TfR) has been detected in different types of rapidly 
proliferating tumors.168 Accordingly, opportune surface functionalization with transferrin (Tf) 
has been applied to efficiently deliver drugs to cancer cells. Such modification clearly enhanced 
the cellular uptake and penetration depth of polyethylene glycol–phosphatidyl ethanolamine 
(PEG–PE) micelles67, 68 and poly(amidoamine) (PAMAM) dendrimers61 in MCTS models of 
ovarian carcinoma67, 68 and glioma61 comparatively to the non-functionalized counterparts. The 
more efficient delivery of the loaded drugs (paclitaxel (Ptx))67, 68 or doxorubicin (Doxo)61 
resulted in a significant inhibition of cell proliferation confirmed by reduction of spheroid 
volume and metabolic activity (ATP content). A 6-fold reduction of the IC50 value (8.92 µM vs 
1.35 µM) was measured on the 3D spheroids incubated with Tf-functionalized Ptx-loaded PEG–
PE micelles (as compared to non-targeted ones) but these values were higher than those observed 
in 2D monolayers. These results reflect a reduction of efficacy due to the existence in the MCTS 
of physical barriers to diffusion and a different cells sensitivity due to the 3D spatial 
organization.67  
Reflectance confocal microscopy and synchrotron X-ray fluorescence microscopy (XFM) have 
been used to monitor in quantitative and qualitative manner, the capacity of penetration into 3D 
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breast cancer spheroids (MCF-7 cells) of transferrin-decorated polymer-modified gold 
nanoparticles (100 nm).105 Images revealed that although functionalization with human Tf 
increased the amount of internalized NPs compared to controls (i.e., bovine transferrin 
functionalized particles and naked ones), after 48 h the penetration of functionalized NPs was 
however limited the a depth of 50 µm thus representing a real issue for further therapeutic 
applications due to their incapacity to diffuse in the tumor core.105  
 
2.3.6.2. Folic acid-targeted nanocarriers 
As previously observed for the transferrin receptor, also the folate receptor is largely expressed 
in cancer cells thus making the functionalization with folic acid (FA) a widely applied approach 
to enhance the ligand-mediated uptake by cancer cells.55, 57, 94, 107 3D tumor spheroids have been 
employed to assess the influence of the folic acid density at the NP surface in the cell targeting 
capacity, internalization and tumor penetration of polymer/DNA complexes (polyplexes) made 
by the assembly of DNA with poly(amidoamine)-poly(ethylenimine) (PME) copolymers 
conjugated to FA functionalized PEG (PME−(PEG-FA)). FA functionalization should enable to 
overcome the reduction of cellular uptake caused by the PEG chains (the so-called PEG-
dilemma)169 and make these systems valuable tools for efficient gene delivery. Divalent 
modification (PME–(PEG3.4k-FA2)1.72) resulted in a higher receptor mediated uptake and a better 
penetration in HEK293T human embryonic kidney spheroids comparatively to mono-
functionalized (PME–(PEG3.4k-FA1)1.66) and non-functionalized nanocarriers (PME–
(PEG3.5k)1.69) (Fig. 9a-c).
94 Indeed, although all polyplexes were found up to 380 µm in depth, 
the divalent FA modification allowed to achieve a better cell internalization (Fig. 9d).  
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The in vitro-in vivo predictive capacity of the 3D models in the evaluation of the FA 
functionalized nanocarriers was recently reported. Indeed, the higher capacity of penetration in 
vitro in 3D neuroblastoma spheroids (SH-SY5Y cells) of FA-decorated Doxo-loaded soy protein 
NPs (SP-NPs)55 or carboxymethyl chitosan-N-3-acrylamidophenylboronic acid (CMCS-
PAPBA)57 NPs resulted in the highest inhibition of tumor growth in H22 tumor-bearing mice. 
 
 
Fig. 9 CLSM images of HEK293T multicellular spheroids 22 h after transfection with (a) PME–
(PEG3.5k)1.69; (b) PME–(PEG3.4k-FA1)1.66, or (c) PME–(PEG3.4k-FA2)1.72 complexes. (d) Relative 
fluorescence intensity (treated group/blank) of HEK293T multicellular spheroids treated with 
PME–(PEG3.5k)1.69, PME–(PEG3.4k-FA1)1.66, or PME–(PEG3.4k-FA2)1.72 complexes for 4 h and for 
further 18 h culture. Reproduced with permission from ref. 94. Copyright 2015 American 
Chemical Society. 
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2.3.6.3. Carbohydrates-targeted nanocarriers 
The natural affinity of dextran for highly glycosylated surfaces has been exploited for achieving 
targeted delivery of ald-dex-Doxo nanoparticles (i.e., aldehyde-dextran polymer conjugated to 
doxorubicin via a pH sensitive bond) to SK-N-BE(2) cells by the interaction with the glycocalyx 
at their surface.126 Investigation of these NPs in 3D neuroblastoma spheroids (∼400-500 μm) 
enabled to discern their potential as drug delivery systems, while it was not evident in 2D 
conditions where the free drug displayed superior cytotoxicity. Such difference disappeared in 
the spheroid model in which a drastic reduction of the free Doxo efficacy was observed while 
that of the ald-dex-Doxo nanoparticles remained unvaried and resulted in a more efficient 
reduction of tumor outgrowth. Such difference was related to the different capacity to overcome 
the encountered biological barriers: after 24 h the free Doxo penetrated up to 50 µm in the 
spheroids while nanoparticles were detected at that depth after 1h only and diffused in the whole 
mass at 4 h. Interestingly, such capacity was exclusive of ald-dex-Doxo nanoparticle and was not 
observed when cells were incubated with dextran based NPs in which the drug has been only 
physically loaded and not covalently linked to the polymer. 
Chitosan has been instead used in the formulation of nanoparticles for specific targeting of the 
CD44 receptor in cancer stem-like cells (CSLCs),53, 60, 77, 89, 106, 122 a rare tumor cell population 
whose resistance to therapeutic agents is a major cause of anticancer treatment failure.170 While 
non-stem cancer cells resistance in 2D cultures is mainly the result of the over expression of 
transmembrane P-glycoprotein transporters,171 in CSLCs a key role is played also by the tumor 
microenvironment.172 Accordingly, relevant preclinical investigations of such functionalized 
nanocarriers required a model capable of mimicking the complex relationship between cancer 
cells and the surrounding environment. Thus, 3D mammary tumor spheroids (i.e., 
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mammospheres) enriched with CSLCs have been successfully created by culturing MCF-7 cells 
with different growth factors and chemicals in order to promote stemness (i.e., self-renewal) and 
epithelial-to-mesenchymal transition (EMT) as demonstrated by the down regulation of the 
estrogen receptors (ER) expression whose role appears to be pivotal in maintaining the epithelial 
differentiation.122, 173 These CD44-expressing mammospheres, which are so far one of the most 
advanced example of 3D system used for polymer nanocarrier evaluation, allowed to assess the 
capacity of chitosan-decorated Pluronic127 nanoparticles to efficiently deliver the loaded 
doxorubicin and to bypass the CSLC drug resistance in vitro. Chitosan functionalization resulted 
in nanoparticles able to selectively target CD44-overexpressing cells in mammospheres (Fig. 
10a) while only a minimal targeting was observed on 3D spheroids made of normal human 
adipose-derived stem cells.122 The better in vitro penetration of such functionalized nanocarriers 
was also confirmed in vivo revealing the highest capacity of inhibition of tumor growth (Fig. 
10b, c).  
CD44 receptors has been targeted also by chondroitin sulfate A–deoxycholic acid-(3-
Aminomethylphenyl) boronic acid (CSA–DOCA–AMPB) NPs, which in addition exploited the 
interaction between boronic acid and sialic acid for efficient delivery of Doxo to human lung 
adenocarcinoma A549 tumors spheroids.60 Penetration observed in vitro by Confocal Laser 
Scanning Microscopy (CLSM) was confirmed in vivo in A549-tumor bearing mice by three-
dimensional near-infrared fluorescence (NIRF) imaging and resulted in significant suppression 
of tumor development.  
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Fig. 10 Structured Illumination Microscopy (Confocal-like) images of specific binding between 
chitosan-decorated doxorubicin-loaded nanoparticles (nDOXO) and mammosphere cells: (a) co-
localization of nDOXO and CD44 receptors; (b) Binding between nDOXO and free Doxo 
(fDOXO) with mammosphere cells. (c) Tumor volume as a function of time for four different 
treatments and image of tumors collected on day 80 after initial drug administration. Reproduced 
with permission from ref.122. Copyright 2015 American Chemical Society. 
 
 
2.3.6.4. Monoclonal antibody-targeted nanocarriers 
Among the plethora of possible strategies for active targeting, the 2C5 monoclonal antibody 
(mAb 2C5) has been employed for its capacity to target several types of tumor cells thanks to the 
interaction with the nucleosomes originated from neighboring apoptotically died tumor cells.174 
Nucleosomes are specifically bound at the surface of tumor cells and are always present in the 
spent media of growing tumor-cell lines as well as in the extracellular fluid of cancer patients.175 
Thus, mAb2C5-functionalized Doxo-loaded polyethylene glycol–phosphatidyl ethanolamine 
(PEG–PE) micelles have been formulated and evaluated in vitro on ovarian cancer MCTS 
constructed by using NCI-ADR-RES cells.136 The key role played by this Doxo-resistant MCTS 
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model relied with the Bcl-2 gene overexpression associated to the three dimensional organization 
of the tumor cells, which closely mimicked the real situation found in patients. Consistent with 
the beneficial effect of mAb2C5 monoclonal antibody conjugation, uniform Doxo distribution 
throughout the spheroids was reached only with the targeted micelles. These same PEG–PE 
micelles have been also functionalized with the single chain fragment variable (scFv) of the 
monoclonal antibody against glucose transporter-1 (GLUT-1) whose overexpression in cancer 
cells relies with their continuous requirement for glucose supply. Accordingly, selective 
targeting of this transmembrane protein might promote the ligand mediated delivery of 
anticancer drugs.66, 73 The in vitro evaluation on 2D monolayer of U87MG glioblastoma cells 
revealed that Doxo and curcumin co-encapsulation in GLUT-1-targeted micelles resulted in a 
significant enhancement of caspases 3 and 7 activity as compared to un-targeted micelles (mono 
drug-loaded and two drugs-loaded).66 Moreover, GLUT-1 targeting improved the penetration of 
PEG–PE micelles into 3D glioblastoma spheroids of U87MG cells in which the Doxo and 
curcumin synergistic effect was confirmed by the highest cytotoxicity (approx. 70% cell death) 
after 5 days of treatment.66 
Estrogen receptor alpha (ER-α) mAb has been instead used to functionalize the surface of 
polyacrylic acid (PAA)-coated ion doped NaYF4:Yb,Er upconversion nanoparticles (UCNPs), 
which have been investigated as potential early-stage cancer detecting agent.83 Such 
functionalization enabled to target MCF7 breast cancer cells spheroid (~500 μm) transplanted in 
a chick embryo chorioallantoic membrane (CAM) aiming at modelling an early stage (i.e., 
diameter smaller than 2 mm) breast cancer. This model not only mimicked the cell-to-cell and 
cell-to-microenvironment interactions but also displayed a novel vascularization around the 
transplanted spheroid. More convenient and easy to handle compared to in vivo animal models, 
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this simplified system allowed a direct microscopic study of the UCNPs-mAb ability to target 
cancer cells and thus detect tumors in vivo at an early-stage. Indeed, following systemic 
administration of UCNPs-mAb via venule injection under a stereomicroscope, a strong 
upconversion luminescence was observed in the spheroid mass. To be noted that only cancer 
cells were targeted and that no accumulation in the other surrounding tissues of the embryo was 
observed, thus demonstrating the optimal selective capacity of such modified nanoparticles.  
 
2.3.6.5. Aptamer-targeted nanocarriers 
Nucleic acid aptamers (DNA and RNA) capable to recognize with high specificity the epithelial 
cell adhesion molecule (EpCAM), a type I membrane protein expressed on the surface of a 
variety of cancer cells176 have been used for surface functionalization of poly(lactide-co-
glycolide) (PLGA)75 and alginate-coated chitosan nanoparticles (CHNPs)74 whose efficiency has 
been evaluated in vitro on 3D MCTS models of breast75 and colon cancer74. Decoration with 
locked nucleic acid (LNA) aptamers allowed CHNPs to reach colon cancer EpCAM-expressing 
cells deeply in the core of both 3D MCTS and tumor experimental models in mice.74 Proof of 
their potential efficient drug carriers was provided using CHNPs loaded with the apoptotic agent 
SR9, a survivin antagonist. Compared to non-functionalized nanoparticles, their efficient 
targeting and penetration capacity resulted in a 5-fold reduction of spheroid volume in vitro 
(after 72 h exposure) and up to 4-times lower tumor volume in colon cancer xenografts in mice 
(at d= 70 post tumor induction).74 
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2.3.6.6. Peptide-targeted nanocarriers 
Specific recognition of ανβ3 integrins has been demonstrated to endow RDG-functionalized 
nanocarriers of targeting capacity toward cancer cells facilitating their internalization.177 
Accordingly, the linear or cyclic version of the RGD has been covalently linked to:  
(i) micelles made by the assembly of the enzyme-sensitive peptide-linked poly(ethylene glycol) 
and partially hydrolyzed poly(β-benzyl l-aspartate) (PEG-GPLGVRGDG-P(BLA-co-Asp) co-
polymer;138  
(ii) mesoporous silica nanoparticles (MSNs) coated with poly(ethylene glycol) (PEG), 
polyethyleneimine (PEI) or chitosan;84  
(iii) PEG-poly(trimethylene carbonate) (PEG-PTMC) nanoparticles;63, 64  
(iv) poly(amidoamine) (PAMAM) dendrimers.146, 149, 150  
The influence of the extent of RGD functionalization was also investigated. For instance the 
transfection efficiency of PAMAM-RGD dendrimers displaying various levels of RDG ligands 
were evaluated in a 3D spheroid model of glioma in comparison to the conventional 2D culture 
of U87MG cells.149, 150 In 2D cultures not any advantage was observed comparatively to the 
naked PAMAM, probably as a consequence of the predominant non-specific interaction 
mediated by the positively charged dendrimers with the cell membrane. However, the evaluation 
in 3D spheroids highlighted the capacity of PAMAM-RGD to strongly interfere with the ανβ3 
integrin-mediated interaction of cells with the ECM, which was directly correlated to the number 
of ligands conjugated to PAMAM. As a consequence of the reduced adhesion, RGD 
functionalization facilitated the penetration and the uptake of PAMAM dendrimers into the 
spheroid model although it did not result in a significant gene silencing.149 
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In addition to the capacity of interaction with integrins, conferred by the RGD sequence, the so 
called tumor penetrating peptides (TPP)177, 178 display a C- terminal sequence R/KXXR/K know 
as C-end rule (CendR).62, 63, 80 Together, these two sequences mediate an active transport through 
tumor vessels and within the extravascular tumor tissue by interaction first with the αvβ3-integrin 
and successively with the neuropilin-1 receptor (NRP).59, 80 Clearly such modification represents 
a valuable approach for increasing the penetration of nanocarriers in the tumor mass.56, 62, 117 
Among the TPP, the iRGD has been physically adsorbed onto boronic acid-rich chitosan-poly(N-
3-acrylamidophenyl boronic acid) (CS-PAPBA) nanoparticles,117 or covalently linked to 
Pluronic F127 coated paclitaxel nanocrystals.56 CLSM images of spheroids exposed to 
fluorescently TPP-functionalized nanocarriers revealed an intense signal, which spread from the 
periphery toward the center of the spheroids demonstrating their superior capacity of penetration 
and accumulation leading to an efficient drug delivery confirmed in vitro by the reduction of 
spheroid volume and in vivo by inhibition of tumor progression (Fig.11).56,62,89,117  
The use of the simple CendR motif with the RGERPPR sequence has been also proposed to 
increase the penetrating capacity of poly(ethylene glycol)–polyethylenimine/ plasmid DNA 
complexes resulting in a higher accumulation into a glioma spheroid model (U87MG cells) 
compared to the-non functionalized counterpart. Nevertheless whether the peptide could also be 
efficient in improving the transfection efficacy in this 3D model, still needs to be verified.80  
Cell penetrating properties are also displayed by the interleukin-13 peptide (IL-13p) capable of 
specific recognition of the IL13Rα2, a tumor-restricted receptor overexpressed in gliomas. 
Functionalization of poly(ethylene glycol)- poly(ε-caprolactone) (PEG-PCL) nanoparticles with 
this peptide (ILNPs) resulted in an enhanced cell-uptake and penetration in U87MG spheroids.78 
A 3-fold higher tumor accumulation was obtained in vivo compared to un-functionalized 
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nanoparticles, which resulted in a better docetaxel delivery and a significant reduction of tumor 
weight compared to the other treatments (saline, free drug and drug-loaded naked NPs).78 
Endowing these NPs of dual targeting properties by functionalization with both IL-13p and RGD 
peptides further improved their penetration ability in C6 glioma spheroids as well as in vivo in 
orthotopic glioma-bearing mice.79  
 
 
Fig. 11 (a) CLSM images of SH-SY5Y MCTS incubated with free Doxo, Doxo-loaded CS-
PAPBA NPs and Doxo-loaded iRGD-CS-PAPBA NPs for 2 h, 4 h and 8 h, respectively. (b) 
In vivo tumor growth curves of H22 tumor-bearing mice that received different treatments. Data 
are represented as mean ± SD (n = 10). * Represents P < 0.05 since the 7th day and ** represents 
P < 0.01 since the 11th day. Reproduced with permission from ref. 117. Copyright 2013 
American Chemical Society 
 
2.4. Use of 3D MCTS to evaluate macromolecules-loaded nanomedicines  
Polymer-based nanomedicines have been investigated for the delivery of proteins or DNA/RNA 
molecules, whose application in clinical settings is strongly limited by (i) inappropriate size and 
surface charge; (ii) low stability against enzymatic degradation and (iii) low cell membrane 
permeability.179, 180  
A variety of polymer/siRNA and pDNA polyplexes have been constructed and evaluated in 3D 
models demonstrating their efficiency as drug carriers. Complexation has been realized for 
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instance with (i) poly(amidoamine) (PAMAM) dendrimers;92, 149 (ii) folate-functionalized- 
poly(ethylene glycol)- polyamidoamine-polyethylenimine (PME-(PEG-FA)) copolymers94 (see 
also 2.3.6.2); (iii) poly(L-lysine);118 (iv) PEG-b-poly(N-substituted asparagine) 
copolymers(PEG-b-P[Asp(DET));131 (v) triblock poly(2-ethyl-2-oxazoline)–poly(L-lactide)-g–
poly(ethylenimine) (PEOz–PLA-g–PEI) polymers;108, 109 (vi) mPEG–PEI (CendR-penetrating-
peptide-modified methoxy poly(ethylene glycol)–polyethylenimine) copolymers80 (see also 
2.3.6.6.); (vii) folate-poly(ethylene glycol) (PEG)-Amino Acid Modified Chitosan (CM-PFA)107 
or (viii) poly[(N,N-dimethylamino) ethyl methacrylate] (PDMAEMA)-derivatized albumin.93,116  
The pioneering studies of Kataoka and coworkers have highlighted the utility of human 
hepatocarcinoma multicellular spheroids (HuH-7 cells) for the long-term evaluation of the 
transfection efficacy achieved using polyplex micelles as gene delivery systems.118, 131 In 
particular core-shell type micelles assembled through electrostatic interactions between poly(L-
lysine) and lactosylated poly(ethylene glycol)-siRNA conjugate (lac-PEGylated polyplexes)118 or 
pDNA and PEG-block- poly(N-asparagine) copolymers (PEG-b-P[Asp(DET)])131 have been 
investigated. Only the 3D MCTS spheroids, which can be maintained in culture for several 
weeks, allowed to carry out an extended analysis of gene expression/suppression under 
conditions close to those observed in vivo in solid tumors.118 On the contrary, such time 
dependent studies could not be performed on 2D monolayer cultures as consequence of cell-cell 
contact-induced arrest and viability decrease that prevented the monitoring of a prolonged gene 
expression.131 Thus, it was possible to observe that the delivery of the RecQL1 siRNA using the 
lac-PEGylated polyplexes allowed an efficient suppression of gene expression, which resulted in 
the inhibition of spheroid growth for up to 21 days.118 Using the same 3D model it was possible 
to demonstrate that pDNA-loaded PEGylated polyplexes penetrated in the spheroids and stably 
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induced the expression of the encoded yellow fluorescent protein Venus for more than 10 
days.131 
Successful prediction of in vivo transfection efficiency was obtained following evaluation in 
MDA-MB-231 breast cancer spheroids of heptafluorobutyric acid modified generation 4 (G4) 
poly(amidoamine) (PAMAM) dendrimers (G4-F735) loaded with a plasmid encoding for the 
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) gene.92 Improved gene delivery 
and better performance, compared to both naked pTRAIL and conventional transfection reagent 
poly(ethylene imine) (PEI) were confirmed in vitro by the complete degradation of the MDA-
MB-231 spheroids after 7 days of treatment (Fig. 12a) and in vivo by suppression of tumor 
growth in a subcutaneous model of luciferase expressing MDA-MB-231 cells (Fig. 12b).92 
The usefulness of stimuli-responsive approaches was assessed by Gaspar and coworkers.108, 109 
Using minicircles DNA (mcDNA), micelleplexes have been constructed by self-assembly with 
poly(2-ethyl-2-oxazoline)–poly(L-lactide)-g–poly(ethylenimine) (PEOz–PLA-g–PEI) triblock 
co-polymer or its bioreducible analogue (PEOz–PLA-g–PEI-SS), which allowed the formulation 
of stimuli-responsive micelles thanks to the introduction of redox sensitive bonds.108 Both 
systems displayed good penetration ability and negligible cytotoxicity in 3D MCTS models of 
melanoma (B16F12 cells), cervix carcinoma (HeLa cells)108 and breast cancer (MCF-7 cells).109 
Nevertheless, confocal images of 3D HeLa and B16F10 spheroid sections revealed that 
bioreducible micelleplexes enhanced GFP gene expression thanks to a higher mcDNA release 
following rapid intracellular reduction of the disulfide linkages.108  
 
46 
 
 
Fig. 12 (a) Optical images of MDA-MB-231 MCTS treated with fresh medium (control), naked 
pTRAIL (pTRAIL), poly(ethylene imine)/pTRAIL complex (PEI/pTRAIL) and G4-
F735/pTRAIL complex (G4-F735/pTRAIL) at different time points. (b) Time-elapsed evolution 
of tumor sizes in vivo. Reproduced with permission from ref. 92. Copyright 2016 Royal Society 
of Chemistry. 
 
2.5. Miscellaneous nanocarriers evaluated on 3D MCTS 
Surface modification of inorganic nanoparticles with various polymer might make possible their 
use as theranostic systems for efficient delivery of therapeutic molecules and precise monitoring 
of the response.81 In this view, coating of iron oxide nanoparticles (IONPs, MRI contrast agent) 
with poly(4-O-acryloyl benzaldehyde)-poly(oligoethylene glycol acrylate) P(HBA)-b-P(OEGA) 
block copolymers allowed their stabilization as well as the covalent conjugation of doxorubicin 
via a pH-sensitive bond, which assured drug release in acidic environment (pH 5.5).81 3D optical 
sectioning by Multi-Photon microscopy of multicellular spheroids made of lung (H129) or breast 
(MCF7) cancer cells clearly showed the fluorescence of Doxo-loaded IONP@P(HBA)-b-
P(OEGA) nanoparticles uniformly spread across the spheroid tissue highlighting a complete 
penetration after 17 h of incubation; on the contrary, free Doxo accumulated in the periphery 
reaching a maximal depth of 40 μm only (Fig. 13).81  
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Fig. 13 3D images of MCF-7 spheroids after incubation with (a) free Doxo and (b) Doxo-loaded 
IONP@P(HBA)-b-P(OEGA) for 17 h. The representative confocal images (left) were taken 
every 5 μm section from the top to bottom in the middle of an intact spheroid, whereas the 3D 
image (right) was reconstructed using Imaris software. Reproduced with permission from ref. 81. 
Copyright 2013 American Chemical Society. 
 
 
In real time monitoring of tumor response to treatment is the goal pursued by Oishi and 
coworkers with the formulation of a PEGylated nanogel containing gold nanoparticles in the 
cross-linked poly[2- (N,N-diethylamino)ethyl methacrylate] (PEAMA) core in which, the 
fluorescein isothiocyanate (FITC) was linked to the PEG chains using the Asp–Glu–Val–Asp 
(DEVD) peptide sequence as caspase-3-cleavable linker.156 Based on the Fluorescence 
Resonance Energy Transfer (FRET) between gold nanoparticles (i.e., fluorescent quencher) and 
FITC, such system behaved as a caspase-3-responsive apoptosis sensor for precise in vitro 
monitoring of the activity of apoptosis-inducing agents. The proof of concept has been provided 
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using human hepatocyte MCTS (HuH-7 cells), which have been incubated with nanogels for 24 
h prior exposure to apoptotic drug staurosporine for 4 h. Intracellular caspase activation triggered 
FITC release from the nanogels and the dequenching of the fluorescent signal, which allowed to 
assess the early stage activation of the induced apoptotic pathway. 
The application of nanodiamonds (ND) as drug delivery systems is currently strongly limited by 
their tendency to agglomerate and precipitate in solution. Thus whether surface modification 
with polymers might offer beneficial effect has been explored by grafting of poly(1-
Omethacryloyl-2,3:4,5-di-O-isopropylidene-β-D-fructopyranose) (poly-(1-O-MAipFru)62) onto 
the surface of amine-functionalized ND. Such approach should improve their stability and allow 
a successful loading of doxorubicin.157 When evaluated in 2D monolayer cultures of MCF-7 and 
MDA-MB-231 breast cancer cells a clear superiority of the free drug over the NDs was 
observed. However, in 3D breast cancer MCTS (MCF-7 cells) long term exposure (8 days) to the 
Doxo-loaded poly(1-O-MAFru)62-ND resulted in higher cytotoxicity compared to the free drug 
which can be justified by the deeper penetration of NDs in spheroids and the sustained release of 
the drug. On the contrary the free Doxo was rapidly internalized by the proliferating cells of the 
outer layers of the spheroids and the consequent cell death hindered further penetration.157  
 
3. Combining 3D MCTS and polymer scaffolds 
3D tumor models made of multicellular spheroids surrounded by a polymer scaffold have been 
also proposed as alternative to simple spheroids suspended in cell culture medium. In these 
systems the scaffold building materials create a matrix around the spheroid capable to mimic in 
vitro the microenvironment surrounding the tumors in vivo. Accordingly, this additional barrier 
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may offer the possibility to better discern the capacity of various nanocarriers to diffuse and to 
reach the cancer cells. 
One of the simplest strategies consisted in embedding preformed spheroids into a collagen gel. 
Such system enabled for instance to highlight the better efficacy of paclitaxel loaded into pH 
sensitive NPs (i.e., espansile NPs)181 compared to the free drug, while this difference did not 
appear in 2D cultures. Indeed, the latter did not display any difference in the cell response 
independently of the drug administration method (free drug solution vs drug-loaded 
nanocarrier).65 On the contrary, in 3D cultures, drug-loaded nanoparticles induced a more 
important slowing of the spheroid growth, which mirrored the inhibition of tumor progression 
obtained in vivo in tumor-bearing mice.181 
In another 3D spheroid design a single cell suspension has been mixed with collagen before 
gelification and cells aggregated over time inside the matrix in form of spheres. Again, while no 
differences were observed in 2D between the free drug (5-fluorouracil) and the drug-loaded 
micelles on the contrary, thanks to the presence of the collagen matrix which mimicked the 
tumor ECM, the 3D model enabled to reveal the limited diffusive capacity of micelles (152 nm) 
compared to the small molecules that led to a lower cytotoxicity.182 Same strategy has been 
applied by mixing prostate cancer cells with hyaluronic acid,183 one of the components of the 
stroma associated to this tumor in vivo, which not only provided structural support but also 
strongly influenced tumor cell morphology, gene expression and tumorigenic potential.184 For 
instance, cell cultured in this 3D scaffold displayed higher expression of multidrug resistance 
proteins, probably as result of the limited availability of oxygen and nutrients. Accordingly, 
while in the 2D cultures the free drug (doxorubicin) easily reached the nucleus and exerted its 
therapeutic activity, in 3D the sensitivity to the free doxorubicin was reduced (5 µM vs 15 µM, 
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respectively). Contrariwise, independently of the culture conditions the response to Doxo-loaded 
PEG-PCL NPs was not modified and analogous IC50 values were measured (11µM vs 12.3 µM, 
respectively) probably thanks to the capacity of these NPs (54 nm diameter) to overcome the 
MDR while the free drug undergo to a rapid efflux, which reduced its the efficacy.183 
 
4. Combining 3D MCTS and microfluidic devices 
Undoubtedly, compared to simplistic 2D cultures the above described 3D systems enabled a 
more predictive in vitro screening of nanoscale systems for drug delivery. Nevertheless, due to 
the lack of fluid dynamics these set ups mimic only a static condition. To face this issue 
microfluidic devices, which combine 3D culture and controlled flow conditions, have been 
recently developed with the aim: (i) to assess how physico-chemical parameters influence the 
transport through tumor biological barriers under dynamic conditions and (ii) to provide 
information on the optimal design required to achieve a successful tumor accumulation.185, 186  
For instance, a tumor-on-a-chip device allowed the passage from a static spheroid culture to a 
dynamic situation by placing a spheroid in the channel of a two layers polydimethylsiloxane 
(PDMS) chip (Fig. 14a).185 By tuning the flow rate in the device, fluid velocities and shear 
stresses similar to the blood flow in capillary vessels (75-675 µm/s) or the interstitial flow inside 
a tumor (0.1-3 µm/s) could be reproduced in a controllable manner. Exposure of spheroid to 
PEGylated nanoparticles of different sizes under stationary flow revealed interstitial 
accumulation only of the smaller NPs (40 nm) while the larger ones (110 nm), bigger than the 
ECM pores, were excluded (Fig. 14b,c). However, accumulation was only transient and 
nanoparticles flowed out after flushing, confirming that surface modification with PEG chains 
hindered the establishment of specific interactions with cells and ECM components. On the 
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contrary no efflux was observed following NP functionalization with transferrin and 40 nm 
nanoparticles reached up to 15-fold increase of tumor accumulation comparatively to non-
functionalized NPs. It was also observed that an increase of the flow rate resulted in 
accumulation in the external spheroid layer, forming a tissue-fluid interface reservoir but that did 
not affect the depth of NP penetration. When the NPs were then tested in vivo, in a tumor bearing 
mice, the same size discriminating effect was recorded, with a better accumulation of small NPs 
(50 nm) compared to the larger ones (160 nm). However functionalization did not led to any 
significant advantage and both targeted and non-targeted 50 nm NPs displayed similar tumor 
accumulation level (Fig. 14d,e). Such contradiction with the results obtained in vitro clearly 
highlighted a limit of the 3D models, which cannot fully reproduce the complexity of living 
organisms and the behavior of NPs after intravenous administration. Thus, although evident that 
3D models would allow a more relevant preclinical screening of nanomedicines compared to 2D 
cultures, at present they cannot completely replace the in vivo experimentation.  
Another proposed approach consisted in the loading of matrigel-embedded preformed spheroids 
in the central channel of a microfluidic device, while continuous medium addition in the lateral 
channels recreated some blood flow conditions. This allowed to assess in dynamic conditions 
treatment responses to doxorubicin in free from and loaded into micelles (Fig. 15).187  
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Fig. 14 (a) Schematic of the PDMS microfluidic device on a microscope stage. (b) Schematic 
(left) and image (right) of 40 nm fluorescent PEG-NPs administered for 1 h at 50 μL/h entering 
the spheroid and accumulating in the interstitial spaces (arrows). Scale bar: 100 μm. (c) 
Schematic (left) and image (right) of 110 nm fluorescent PEG-NPs administered for 1 h at 
50 μL/h being excluded from the spheroid. Scale bar: 100 μm. (d) Representative images of 
tumor fluorescence from mice injected with NPs in the tail vein at 48 h post-injection. (e) 
Quantification of animal fluorescence at 2 and 48 h using whole animal images. Reproduced 
with permission from ref. 185. Copyright 2013 Nature Publishing group. 
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Fig. 15 (a) Bright field image of the microfluidic channel. The black arrow shows the direction 
of medium flow. Scale bar: 300 μm. (b) Bright-field image of the MCTS in the microfluidic 
channel. (top) The MCTS in matrigel prior to Doxo-HCl treatment. (bottom) Real-time, enlarged 
views of the MCTS during 24 h of treatment with Doxo-HCl. Scale bar: 50 μm. Reproduced with 
permission from ref. 187. Copyright 2013 American Chemical Society. 
 
Conclusion and perspectives 
Through many literature examples this review has unambiguously highlighted that simple 2D 
monolayers cultures do not allow complete understanding of the therapeutic potential of polymer 
nanomedicines while the application of 3D tumor models in preclinical evaluation would provide 
more accurate results, predictive of the in vivo pharmacological efficacy. The key features of the 
MCTS (e.g., presence of ECM, diffusive gradients, complex cell signaling, drug resistance and 
metabolic adaptation) undoubtedly enable to evaluate the nanomedicines in a condition closer to 
the clinical reality. But it cannot be ignored that the majority of tumor spheroids used in 
literature are made of cancer cells only and therefore they just represent a rather simplified 
model of the real tumorigenesis. Due to the complexity of the tumor tissues and the cross-talking 
between cancer cells and their microenvironment, advanced models including several cell types 
(e.g., endothelial cells, immune cells, fibroblast etc) and components of the ECM are urgently 
required. Thus, 3D co-cultures47, 48, 188 and microfluidic devices111-113, 185, 186, 189 have been 
developed but further improvements are still needed in order to allow a wider application in 
preclinical investigation. In this context, the accurate characterization (e.g., cell number, long 
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term viability of each cell components, type of ECM proteins, etc.., ) of any developed system is 
mandatory for allowing a reliable interpretation of the obtained results. It is indeed well 
acknowledged that the spheroid size43, 46 as well as the presence of stroma components47, 48, 188 
strongly affect the response to treatment according to the possible development of penetration 
barriers,46-48, 188 chemical gradients and/or necrosis.43 
The availability of microscopy techniques suitable for high resolution imaging of 3D cell 
cultures represents another challenge. Indeed, although widely used, CLSM does not allow the in 
toto study of large 3D samples and the obtained results refer only to penetration into the 
spheroids at the depth of maximum 100-150 µm. A significant improvement in 3D imaging 
should result from Two-Photon (TPM) and Multi-Photon Microscopies (MPM) but the low 
spatial resolution along the optical axis and the incompatibility of certain fluorophores with the 
multi-photon excitation still restrict the applicability of these methods.140, 190 In this challenging 
panorama, LSFM approaches (e.g., Selective Plane Illumination Microscopy (SPIM)) are 
emerging as techniques of choice in life sciences for the imaging of complex and highly 
scattering samples.142-145 Offering the possibility to visualize the spheroids in their entirety with a 
sub-cellular resolution191, 192 the SPIM technique clearly enables to achieve a superior degree of 
information in the screening of nanomedicines pharmacological efficiency.47 The penetration 
ability of nanomedicines can be assessed over the whole 3D MCTS mass and a dynamic study of 
the anticancer response is also possible with the time lapse imaging of living spheroids. 
Unfortunately, such advanced techniques require highly specialized technologies whose 
availability remains still limited.  
It is evident that labor-intensive handling, time-consuming procedures, instrumental limitations 
and cost still hinder the routinely use of advanced 3D models in drug discovery programs. 
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Noteworthy is that, to the best of our knowledge, not any promising nanomedicine currently in 
clinical trials has been tested in 3D MCTS during in vitro pre-clinical studies. Nevertheless, 
advances in the near future are expected to rapidly support their widespread use, thus making the 
in vitro drug screenings more predictive and able to sieve out underperforming compounds in the 
early pre-clinical stage. 
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